
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana's increased earnings per share (EPS) estimate for 2025, revised upwards to $17.06 from $16.26, reflects strong second-quarter results and updated guidance, indicating robust financial performance. The company anticipates year-over-year earnings growth for 2027, supported by the implementation of margin initiatives, despite expecting no recovery of bonus payments related to their star rating program. Additionally, Humana's strong competitive position is reinforced by its above-industry star rating in the Medicare Advantage program, which positions the company favorably amid ongoing regulatory and reimbursement changes.
Bears say
Humana's outlook is precarious primarily due to anticipated declines in earnings per share (EPS) for 2026, which are projected to drop slightly from 2025 levels despite management's margin improvement initiatives. The company faces multiple downside risks, including increased competition in Medicare Advantage (MA), inadequate reimbursement rates, and declining MA Star ratings, which could further jeopardize its financial performance. Additionally, there is a concerning expectation that the necessity for increased investments to support Stars recovery could result in FY27 EPS falling approximately 10% short of current estimates.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares